RICHMOND, Va., December 19, 2017- Virginia Bio, the premier statewide non-profit association representing the life science industry in the Commonwealth of Virginia, has elected two
LOUISVILLE, Ky. and CAMBRIDGE Mass., Dec. 08, 2017 – Apellis Pharmaceuticals,Inc. (Nasdaq:APLS), a clinical-stage biopharmaceutical company developing a platform of novel therapeutic compounds for the
Acquisition Marks Further Success for the Epidarex Portfolio Bethesda, Md., December 7, 2017 – Epidarex Capital (“Epidarex”), an early-stage, transatlantic life science venture fund, today
An interview with Sinclair Dunlop, Managing Partner at Epidarex Capital Sinclair Dunlop, Managing Partner at transatlantic venture capital firm Epidarex Capital, talks to Biotechand Money
Bethesda, Maryland, USA, and Edinburgh, UK: Epidarex Capital (“Epidarex”), an early-stage, transatlantic life science venture fund, is pleased to announce the initial public offering (“IPO”)
Crestwood, Kentucky, Nov. 13, 2017 – Apellis Pharmaceuticals, Inc. (NASDAQ:APLS), a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat disease through
Crestwood, Kentucky, Nov. 08, 2017 – Apellis Pharmaceuticals, Inc. (NASDAQ:APLS), a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat disease
Device May Improve Quality and Frequency of Repair Baltimore, Maryland – A new study has found that a pioneering device to repair heart valves is
Corporate venture fund invests EUR 4 million (USD 5 million) into Topas Financing to accelerate clinical trials in autoimmune diseases Detlev Mennerich, Ph.D., Investment Manager
Bethesda, Maryland, USA, and Edinburgh, UK: Epidarex Capital (“Epidarex”), an early-stage, transatlantic life science venture fund, announces the appointment of Dr. William R Sellers, William